Together, present results demonstrate that CRHBP is a novel suppressor of ccRCC and further extend the notion that the underlying mechanisms of CRHBP anti-tumor capacity are associated with NF-κB pathway and p53-mediated mitochondrial apoptosis pathway. The gene discussed is TP53; the disease is nonpapillary renal cell carcinoma.